Physician profile
Woun Hui Seok
NPI 1043303704
$25,841.39
in general payments reported to CMS, 2019-2025
60 companies · $2,589 in 2025
The $2,589 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,456 · 2020: $3,519 · 2021: $4,501 · 2022: $4,292 · 2023: $3,249 · 2024: $3,236 · 2025: $2,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,994 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,993.93 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,363.40 | 2019-2025 | Evenity, Repatha, Prolia |
| Abbvie INC. | $3,285.03 | 2019-2025 | Linzess, Vraylar, Qulipta |
| Amarin Pharma, INC. | $1,751.21 | 2019-2023 | |
| Pfizer INC. | $1,480.18 | 2019-2025 | |
| Radius Health, INC. | $1,421.62 | 2019-2024 | Tymlos |
| Sanofi-Aventis U.S. LLC | $1,335.76 | 2019-2023 | |
| Novo Nordisk INC | $1,252.71 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $1,167.44 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Gilead Sciences, INC. | $1,076.45 | 2019-2025 | Vemlidy |
| Lilly USA, LLC | $828.48 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $794.63 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $642.19 | 2023-2025 | Gemtesa, Myfembree |
| Astellas Pharma US INC | $624.02 | 2019-2025 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company Ltd. | $616.79 | 2022 | |
| Merck Sharp & Dohme LLC | $498.50 | 2019-2022 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $477.92 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $457.41 | 2019-2023 | Xarelto |
| Sunovion Pharmaceuticals INC. | $419.17 | 2021-2022 | |
| Glaxosmithkline, LLC. | $369.95 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $339.81 | 2019-2025 | Jardiance |
| Ardelyx, INC. | $316.96 | 2023-2025 | Ibsrela |
| Allergan, INC. | $296.69 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $293.11 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Aimmune Therapeutics, INC. | $247.09 | 2024-2025 | Zenpep |
| Scilex Pharmaceuticals INC. | $233.60 | 2020-2024 | Ztlido |
| Novartis Pharmaceuticals Corporation | $185.52 | 2019-2021 | |
| Esperion Therapeutics, INC. | $179.35 | 2021-2025 | Nexletol |
| Ibsa Pharma INC. | $174.91 | 2022-2024 | Tirosint, Licart, Licart |
| Arbor Pharmaceuticals, INC. | $145.05 | 2019-2021 | |
| Exact Sciences Corporation | $132.16 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $129.86 | 2022-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $118.76 | 2019-2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $112.74 | 2019-2021 | |
| Vivus LLC | $112.62 | 2021-2022 | |
| Vbi Vaccine (Delaware) INC. | $103.56 | 2023 | Prehevbrio |
| Biohaven Pharmaceuticals, INC. | $103.36 | 2021 | |
| Alexion Pharmaceuticals, INC. | $84.27 | 2020-2022 | |
| Alk-Abello, INC | $54.29 | 2024 | Odactra, Ragwitek, Grastek |
| Otsuka America Pharmaceutical, INC. | $46.00 | 2024 | Rexulti |
| Paratek Pharmaceuticals, INC. | $44.46 | 2020 | |
| Almatica Pharma LLC | $43.81 | 2021-2025 | Teriparatide, Loreev Xr |
| Xeris Pharmaceuticals, INC. | $38.45 | 2023 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $35.62 | 2019-2022 | |
| Abbott Laboratories | $33.27 | 2023-2025 | Eterna, Freestyle Libre 3 |
| Azurity Pharmaceuticals, INC. | $32.70 | 2023 | Horizant |
| Inspire Medical Systems, INC. | $32.53 | 2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $31.71 | 2024-2025 | Voquezna |
| Genentech USA, INC. | $31.41 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.02 | 2024-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.82 | 2019 | |
| Redhill Biopharma INC. | $26.29 | 2020-2024 | Talicia |
| Corium, LLC | $23.61 | 2023 | Adlarity |
| Lundbeck LLC | $22.86 | 2022 | |
| Medtronic, INC. | $21.15 | 2024 | Intellis Adaptivestim |
| Tempus Ai, INC | $19.85 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.00 | 2019 | |
| Dermira, INC. | $15.03 | 2020 | |
| Ethicon US, LLC | $13.87 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.46 | 2023 | Quviviq |
| Hologic Sales and Service, LLC | $12.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Woun Seok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.